Regenxbio Book Value Per Share Growth & History (RGNX)
Regenxbio's book value per share was $2.02 for fiscal 2025.
View full Regenxbio company overviewRegenxbio annual book value per share history
| Fiscal year | Period ended | Book value per share | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $2.02 | -$3.22 | −61.48% |
| 2024 | 2024-12-31 | $5.24 | -$1.84 | −25.96% |
| 2023 | 2023-12-31 | $7.08 | -$4.84 | −40.63% |
| 2022 | 2022-12-31 | $11.92 | -$5.92 | −33.19% |
| 2021 | 2021-12-31 | $17.84 | $7.76 | +77.03% |
| 2020 | 2020-12-31 | $10.08 | -$2.09 | −17.18% |
| 2019 | 2019-12-31 | $12.17 | -$1.92 | −13.61% |
| 2018 | 2018-12-31 | $14.09 | $8.24 | +140.88% |
| 2017 | 2017-12-31 | $5.85 | -$0.26 | −4.26% |
| 2016 | 2016-12-31 | $6.11 | -$2.13 | −25.86% |
| 2015 | 2015-12-31 | $8.24 | $15.15 | — |
| 2014 | 2014-12-31 | -$6.92 | -$0.91 | — |
| 2013 | 2013-12-31 | -$6.00 | — | — |
Regenxbio quarterly book value per share
| Fiscal quarter | Period ended | Book value per share | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $1.32 | -$2.92 | −68.76% |
| Q1 2026 | 2026-03-31 | $0.41 | -$5.06 | −92.53% |
| Q4 2025 | 2025-12-31 | $2.02 | -$3.22 | −61.48% |
| Q3 2025 | 2025-09-30 | $3.19 | -$2.90 | −47.58% |
| Q2 2025 | 2025-06-30 | $4.24 | -$2.82 | −39.95% |
| Q1 2025 | 2025-03-31 | $5.47 | -$2.49 | −31.32% |
| Q4 2024 | 2024-12-31 | $5.24 | -$1.84 | −25.96% |
| Q3 2024 | 2024-09-30 | $6.09 | -$2.17 | −26.28% |
| Q2 2024 | 2024-06-30 | $7.06 | -$2.24 | −24.10% |
| Q1 2024 | 2024-03-31 | $7.97 | -$2.74 | −25.56% |
| Q4 2023 | 2023-12-31 | $7.08 | -$4.84 | −40.63% |
| Q3 2023 | 2023-09-30 | $8.25 | -$4.77 | −36.62% |
| Q2 2023 | 2023-06-30 | $9.30 | -$5.30 | −36.30% |
| Q1 2023 | 2023-03-31 | $10.70 | -$5.34 | −33.31% |
| Q4 2022 | 2022-12-31 | $11.92 | -$5.92 | −33.19% |
| Q3 2022 | 2022-09-30 | $13.02 | $2.23 | +20.67% |
| Q2 2022 | 2022-06-30 | $14.61 | $2.69 | +22.53% |
| Q1 2022 | 2022-03-31 | $16.05 | $3.00 | +23.00% |
| Q4 2021 | 2021-12-31 | $17.84 | $7.76 | +77.03% |
| Q3 2021 | 2021-09-30 | $10.79 | -$0.32 | −2.88% |
| Q2 2021 | 2021-06-30 | $11.92 | $1.25 | +11.72% |
| Q1 2021 | 2021-03-31 | $13.05 | $1.75 | +15.47% |
| Q4 2020 | 2020-12-31 | $10.08 | -$2.09 | −17.18% |
| Q3 2020 | 2020-09-30 | $11.11 | -$1.60 | −12.60% |
| Q2 2020 | 2020-06-30 | $10.67 | -$2.79 | −20.72% |
| Q1 2020 | 2020-03-31 | $11.30 | -$2.01 | −15.08% |
| Q4 2019 | 2019-12-31 | $12.17 | -$1.92 | −13.61% |
| Q3 2019 | 2019-09-30 | $12.71 | -$1.12 | −8.12% |
| Q2 2019 | 2019-06-30 | $13.46 | $3.63 | +36.92% |
| Q1 2019 | 2019-03-31 | $13.30 | $3.92 | +41.77% |
| Q4 2018 | 2018-12-31 | $14.09 | $8.24 | +140.88% |
| Q3 2018 | 2018-09-30 | $13.84 | $7.58 | +121.15% |
| Q2 2018 | 2018-06-30 | $9.83 | $2.97 | +43.25% |
| Q1 2018 | 2018-03-31 | $9.38 | $2.34 | +33.30% |
| Q4 2017 | 2017-12-31 | $5.85 | -$0.26 | −4.26% |
| Q3 2017 | 2017-09-30 | $6.26 | -$0.55 | −8.08% |
| Q2 2017 | 2017-06-30 | $6.86 | -$0.55 | −7.44% |
| Q1 2017 | 2017-03-31 | $7.04 | -$0.88 | −11.12% |
| Q4 2016 | 2016-12-31 | $6.11 | -$2.13 | −25.86% |
| Q3 2016 | 2016-09-30 | $6.81 | -$1.62 | −19.27% |
| Q2 2016 | 2016-06-30 | $7.41 | — | — |
| Q1 2016 | 2016-03-31 | $7.92 | — | — |
| Q4 2015 | 2015-12-31 | $8.24 | $15.15 | — |
| Q3 2015 | 2015-09-30 | $8.43 | — | — |
| Q4 2014 | 2014-12-31 | -$6.92 | — | — |
Regenxbio book value per share trends
Over the last five fiscal years, Regenxbio's book value per share decreased from $10.08 to $2.02, a change of -$8.06. The latest reported quarter, Q2 2026, shows $1.32.
What book value per share means
Book value per share estimates the common shareholders’ accounting equity represented by each share. It can help compare a company’s balance-sheet value over time, although market value can differ substantially from book value.
How book value per share is calculated
TickerStat calculates book value per share as SEC-reported common shareholders’ equity divided by reported period-end common shares. Preferred equity is subtracted when separately reported, and basic weighted-average shares are used only when period-end shares are unavailable. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Regenxbio source filings ↗